A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.
about
Structural Insights into Neonatal Fc Receptor-based Recycling MechanismsTargeting FcRn for the modulation of antibody dynamicsThe neonatal Fc receptor, FcRn, as a target for drug delivery and therapySafety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy AdultsA cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough.Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxinAnti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model.pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trialsMEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia ModelA novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.A fluorescent imaging method for analyzing the biodistribution of therapeutic monoclonal antibodies that can distinguish intact antibodies from their breakdown productsSafety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignThe development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.Novel therapies and vaccines against the human respiratory syncytial virus.New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.Monoclonal antibodies: technologies for early discovery and engineering.Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.Half-life extended biotherapeutics.Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Global and Local Conformation of Human IgG Antibody Variants Rationalizes Loss of Thermodynamic Stability.Mechanisms of neutralization of a human anti-α-toxin antibody.Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.Passive and active immunization against respiratory syncytial virus for the young and old.A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.Current progress in innovative engineered antibodies.Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates.A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.An antidote approach to reduce risk and broaden utility of antibody-based therapeutics.Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.
P2860
Q27681475-8CD13598-B25C-4BE0-81E1-40004BC1A274Q28080589-F57FA3B5-2FB9-45BA-A480-77523AD6F38CQ28257521-3E9D3335-6C68-4954-AB2B-A063A9F762C2Q28354370-2DB9CAD0-3EDC-4127-88F9-3043E89E2A48Q30825645-B5D26985-CCB4-4F75-BC89-0904FD0E3F97Q31091923-0C4285F4-BDD8-48A0-A2DC-C7A6D8B92459Q31150455-59EB1C29-756D-4ADE-AF9C-40BC92556E01Q34588890-A1C34124-1A9C-494D-B036-F36B1CEF9C29Q34922452-9E483745-EDD7-4C7D-9C96-6A60C915842FQ35080330-D9B97687-B794-4D6C-BC87-1B512D51D963Q35612850-6DDE414D-A7AC-4DEE-A72A-03C61D532F22Q35761061-CD1E6241-1E39-4093-BD84-2B6D3817CF59Q35859999-6813F536-0694-4458-AB7B-8E89B6FD5F56Q36211427-05E18CA7-18B1-495B-8BB3-BD2F1CACAFCFQ36215502-64288C3B-7BF2-45FE-A5AA-C1435508554FQ37669850-1DDA8A3D-4AD2-463D-8349-4D1D473CA345Q37729137-F5C8FDD8-9FA3-427D-BCED-420ED58192B4Q38355263-7255DAC4-D4D1-4574-83BB-3A3B188F4544Q38604787-718414BE-8F28-4093-8A62-C3D1D9DD57B2Q38628928-4BB95187-F8A5-469D-8D54-59893EDD2A12Q38633596-5177A26C-D991-4BE9-879F-385786DFE933Q38671952-16B77AAB-F014-41AF-BD28-6C0F0AB25B5FQ38718049-6B2DB80B-3109-42F1-9123-E996DCA8C3B1Q38728589-6BCB2E4F-AEA0-4A4B-8D1C-C72A4247608EQ38730742-D7A28720-54C9-4280-907D-F79551BFE23AQ38770067-B13330CA-A7CE-455D-810A-A9BF5085B2FDQ38821056-3D70167E-9CD3-4FAA-AC8A-74F955F8CBDAQ38831148-0B811DF7-05CF-4516-9FEE-F200F56E2CD3Q38951896-FC806FC3-545C-449C-A548-47B6D7E0EE4FQ38957590-158049F0-5DC0-4C0B-817A-B0D107D1D3A5Q38969434-2CF54C13-944B-4E52-8C9F-2D9541F29C24Q39318498-63329ABB-265A-4CA0-903D-D642D17D7DFFQ39362187-7E08F7AA-0D30-4D0D-83C8-2EC2FD468927Q39731345-C58CBA26-9F31-472E-95C7-E581DF56C900Q40077818-EBFED7DC-A6A1-488F-B593-C6A9BDD0B282Q40081626-0DE6DD98-FEEC-46EE-97B1-DF30D9EB21E0Q40216493-87129DDB-59C1-4EBB-AE4D-7276297A61DAQ40309222-15B2072B-62C1-4816-B9BC-337502FF739BQ40545249-F3634284-8455-43D0-A848-F7D562139E9FQ41104888-CA931B92-D3BA-49D1-8D9C-79B7D2C28A67
P2860
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel investigational Fc-mod ...... d half-life in healthy adults.
@en
A novel investigational Fc-mod ...... d half-life in healthy adults.
@nl
type
label
A novel investigational Fc-mod ...... d half-life in healthy adults.
@en
A novel investigational Fc-mod ...... d half-life in healthy adults.
@nl
prefLabel
A novel investigational Fc-mod ...... d half-life in healthy adults.
@en
A novel investigational Fc-mod ...... d half-life in healthy adults.
@nl
P2093
P2860
P356
P1476
A novel investigational Fc-mod ...... d half-life in healthy adults.
@en
P2093
Gabriel J Robbie
Genevieve A Losonsky
Kathryn Jensen
M Pamela Griffin
Nita K Patel
Ryan Criste
William F Dall'acqua
P2860
P304
P356
10.1128/AAC.01285-13
P407
P577
2013-09-30T00:00:00Z